Scholar Rock (SRRK) Q4 FY25 earnings call

Scholar Rock is poised for a transformative 2026, driven by the anticipated BLA resubmission and US launch of apitegromab for SMA, alongside advancing its anti-myostatin pipeline. The company is actively preparing for commercialization in the US and Europe, while also strengthening its financial position through a new debt facility. Despite potential initial access challenges, the long-term opportunity for apitegromab is viewed as significant.